BIOMARIN PHARMACEUTICAL INC (BMRN) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — BMRN

Balance Sheet

(in billions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	0.87	2.22	1.25	1.21	1.05	0.68	0.97	0.75	0.79	0.69	0.58	0.76	0.62	0.61	0.62	0.64	0.67
Accounts Receivable	1.06	0.90	0.79	0.86	0.74	0.78	0.69	0.64	0.57	0.61	0.60	0.42	0.47	0.43	0.37	0.42	0.40
Inventory	1.78	1.27	1.38	1.34	1.27	1.18	1.18	1.14	1.03	0.98	0.92	0.84	0.80	0.79	0.75	0.71	0.71
Total Current Assets	3.97	4.61	3.85	3.81	3.47	3.06	3.26	2.99	2.96	2.95	2.84	2.68	2.52	2.39	2.31	2.36	2.29
Property, Plant & Equipment	0.99	0.96	1.04	1.03	1.03	1.05	1.05	1.06	1.07	1.07	1.07	1.05	1.05	1.04	1.02	1.03	1.02
Goodwill	0.66	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20
Intangible Assets	4.88	0.20	0.23	0.24	0.25	0.26	0.27	0.28	0.30	0.31	0.33	0.35	0.37	0.37	0.39	0.39	0.41
Total Non-current Assets*	7.75	3.99	3.76	3.65	3.68	3.79	3.81	3.89	3.80	3.61	3.59	3.58	3.63	3.67	3.67	3.54	3.52
Total Assets	11.72	8.59	7.61	7.46	7.15	6.85	7.07	6.87	6.76	6.56	6.43	6.26	6.15	6.06	5.98	5.90	5.81
Accounts Payable	1.01	0.79	0.80	0.68	0.63	0.72	0.57	0.59	0.67	0.60	0.60	0.49	0.43	0.43	0.47	0.41	0.40
Total Current Liabilities	1.66	0.79	0.80	0.68	0.63	0.72	1.07	1.09	1.16	0.60	0.60	0.52	0.46	0.49	0.51	0.44	0.43
Long-term Debt	4.19	1.43	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Total Non-current Liabilities*	3.74	1.59	0.76	0.74	0.73	0.72	0.71	0.71	0.70	1.18	1.18	1.17	1.18	1.18	1.20	1.21	1.21
Total Liabilities	5.40	2.38	1.56	1.43	1.35	1.44	1.78	1.80	1.86	1.78	1.77	1.70	1.64	1.67	1.71	1.66	1.64
Retained Earnings	0.30	0.26	0.20	0.23	(0.01)	(0.32)	(0.43)	(0.53)	(0.64)	(0.68)	(0.74)	(0.79)	(0.78)	(0.80)	(0.87)	(0.83)	(0.84)
Total Stockholder Equity	6.32	6.21	6.06	6.03	5.79	5.41	5.29	5.07	4.90	4.78	4.66	4.57	4.50	4.39	4.27	4.24	4.16

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Total Revenue	989.71	766.21	874.57	776.13	825.41	745.15	747.31	745.74	712.03	648.83	646.21	581.33	595.28	596.42	537.54	505.34	533.80	519.36	449.81	408.74
Cost of Revenue	202.80	195.00	275.71	140.09	150.09	151.56	136.14	188.46	130.46	125.18	135.48	124.75	128.08	126.55	127.29	116.29	123.13	116.97	119.75	103.54
Gross Profit	786.91	571.21	598.86	636.05	675.32	593.59	611.17	557.28	581.57	523.65	510.73	456.58	467.19	469.87	410.25	389.06	410.67	402.39	330.06	305.21
Research & Development	206.95	178.80	192.41	409.48	161.31	158.73	173.51	184.90	183.79	204.99	206.25	191.31	177.36	171.85	172.75	157.83	158.19	160.84	161.09	157.87
Selling, General & Admin	395.55	258.29	446.21	268.42	232.28	206.12	266.61	253.48	263.03	225.91	275.02	223.93	215.34	223.00	245.74	216.82	196.84	194.62	217.56	183.33
Total Operating Expenses	675.99	441.57	643.47	682.74	398.43	369.69	449.77	443.39	461.12	435.19	496.51	430.92	408.32	410.52	434.75	391.47	371.52	265.07	395.94	358.42
Operating Income	110.92	129.64	(44.61)	(46.69)	276.89	223.89	161.41	113.89	120.45	88.46	14.22	25.66	58.87	59.35	(24.50)	(2.42)	39.15	137.33	(65.88)	(53.22)
Interest Expense	60.73	9.57	--	--	--	--	--	--	--	3.55	6.10	3.78	3.76	3.70	3.63	4.68	3.86	3.81	3.85	3.87
Pretax Income	61.38	141.20	(27.15)	(26.32)	297.87	238.09	169.64	134.44	132.14	105.55	19.33	41.67	70.81	56.76	(17.56)	(1.90)	34.85	134.19	(66.57)	(46.16)
Tax Provision	16.62	35.68	19.42	4.42	57.34	52.40	44.70	28.36	24.96	16.89	(1.05)	1.29	14.77	5.91	(17.31)	4.75	7.19	13.39	(8.68)	(9.67)
Net Income	44.76	105.53	(46.57)	(30.74)	240.53	185.69	124.94	106.08	107.17	88.66	20.38	40.38	56.04	50.85	(0.25)	(6.65)	27.66	120.80	(57.90)	(36.49)
Basic EPS	0.23	0.55	(0.24)	(0.16)	1.25	0.97	0.66	0.56	0.56	0.47	0.11	0.21	0.30	0.27	(0.01)	(0.04)	0.15	0.66	(0.32)	(0.20)
Diluted EPS	0.23	0.54	(0.22)	(0.16)	1.23	0.95	0.65	0.55	0.55	0.46	0.10	0.21	0.29	0.27	0.01	(0.04)	0.15	0.63	(0.31)	(0.20)

Cash Flow Statement

(in billions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Operating Cash Flow	0.17	0.22	0.10	0.37	0.19	0.17	0.19	0.22	0.12	0.05	0.03	0.14	0.07	(0.07)	0.01	0.16	0.06	(0.05)	0.01	0.10
Capital Expenditures	0.03	0.02	0.04	0.03	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.02	0.02	0.02	0.04	0.03	0.03	0.03	0.03	0.02
Free Cash Flow*	0.14	0.20	0.06	0.34	0.17	0.16	0.17	0.20	0.10	0.02	-0.00	0.11	0.05	(0.10)	(0.03)	0.13	0.03	(0.07)	(0.02)	0.08
Investing Cash Flow	(5.10)	0.73	(0.04)	(0.33)	(0.01)	(0.03)	0.08	(0.02)	0.09	(0.01)	(0.06)	(0.05)	0.03	(0.03)	(0.05)	(0.02)	(0.03)	0.09	(0.06)	(0.12)
Financing Cash Flow	2.74	0.81	0.00	-0.00	-0.00	(0.04)	0.00	(0.50)	0.01	(0.04)	0.01	-0.00	0.01	(0.04)	0.01	0.01	(0.01)	(0.03)	0.01	-0.00

* Derived from reported values